ABOS today
$0.20-$0.02 (-7.25%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourSymmetric Triangle
1 hourSymmetric Triangle
15 minStrong Bearish
5 minSymmetric Triangle
Daily trend turns up above $2.52
Key levels
Resistance$0.99
Resistance$0.25
Latest news & SEC filings
SEC FilingAcumen Pharmaceuticals, Inc. filed a report on a major company event (Form 8-K)
All ABOS news →About Acumen Pharmaceuticals
Acumen Pharmaceuticals is a drug developer working on treatments for Alzheimer's disease. Its lead candidate, sabirnetug, is an antibody that targets small clumped forms of the amyloid-beta protein and is in mid-stage testing for patients with early memory and thinking problems linked to Alzheimer's. The company is also developing a brain-penetrating antibody program and a subcutaneous version of sabirnetug with partners.
Based on the company's 10-K filed Mar 26, 2026.
Nasdaq · Healthcare
Acumen Pharmaceuticals, Inc. (ABOS)
What Is the Price Target for ABOS?
SEPT Low Target
$0.85
SEPT Mid Target
$1.00
SEPT High Target
$1.15
Analyst Consensus
$1.00
Is ABOS a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ABOS.
Start Free Trial →Is ABOS Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$1.06
12
Moat Score
NONE
1/9
Piotroski Score
-5.9
Altman Z-Score
What Is Smart Money Doing with ABOS?
Insider Signal
SELLING
0 buys / 7 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
DISTRIBUTING
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Fountain Nathan B | director | Sale | 6,400 | $14K | Jun 9, 2026 |
| Fountain Nathan B | director | Buy | 35,500 | - | Jun 3, 2026 |
| Drapkin Kimberlee C | director | Buy | 35,500 | - | Jun 3, 2026 |
| Stalfort John A III | director | Buy | 35,500 | - | Jun 3, 2026 |
| Porter Derrell | director | Buy | 35,500 | - | Jun 3, 2026 |
| Ives Jeffrey L. | director | Buy | 35,500 | - | Jun 3, 2026 |
| Golumbeski George | director | Buy | 35,500 | - | Jun 3, 2026 |
| Stoppel Laura | director | Buy | 35,500 | - | Jun 3, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | director 10% owner | Buy | 35,500 | - | Jun 3, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ABOS Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-16.96%
FCF Growth YoY
-34.1%
Revenue Trend
UNKNOWN
Dark Pool Trades for ABOS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ABOS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 19:26:45 | $0.20 | 1,800 | $$363 | SELL |
| 19:26:14 | $0.20 | 1,900 | $$384 | SELL |
| 19:22:22 | $0.20 | 1,500 | $$306 | SELL |
| 19:20:16 | $0.20 | 1,300 | $$265 | SELL |
| 19:18:21 | $0.20 | 1,500 | $$307 | BUY |
5 dark pool trades shown · $$2K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for ABOS
PREVIEWSEPT Investing provides real-time options flow tracking for ABOS, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| PUT | $0.5 | Nov 20 | 7 | $$35 | 1 | SWEEP |
| PUT | $2.5 | Nov 20 | 7 | $$235 | 1 | SWEEP |
2 options trades shown · 0% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Acumen Pharmaceuticals, Inc. (ABOS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (7 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ABOS — frequently asked questions
What is ABOS stock price today?
Acumen Pharmaceuticals, Inc. (ABOS) is at $0.20, down 7.25% (-$0.02) at the Nov 13, 2026 close.
Why is ABOS stock moving today?
Latest ABOS news — Nov 5, 2026: Acumen Pharmaceuticals, Inc. filed a report on a major company event (Form 8-K)
What is the ABOS price target?
The average analyst price target for ABOS is $1.00, ranging from $1 to $1, based on 1 analysts. Latest: Citigroup downgrade on Oct 30, 2026.
What do analysts rate ABOS?
Analyst ratings for ABOS: 0 Buy, 2 Hold, 1 Sell — consensus Hold.
Did ABOS beat earnings?
ABOS last reported on Oct 26, 2026: EPS -$0.35 vs -$0.39 expected — a beat of 9.9%.
Does ABOS pay a dividend?
ABOS does not currently pay a dividend.
How much debt does ABOS have?
Acumen Pharmaceuticals, Inc. reported $6M of debt and $53M of cash (Sep 30, 2026).
What are ABOS support and resistance levels?
Resistance: $0.25, $0.99, $1.21.
What are insiders doing with ABOS?
Insider activity: SELLING, 0 buys and 7 sells in the last 90 days.
What is the latest news on ABOS?
Nov 5, 2026: Acumen Pharmaceuticals, Inc. filed a report on a major company event (Form 8-K)